Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/31787
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKoshy, Anoop N-
dc.contributor.authorGiustino, Gennaro-
dc.contributor.authorSartori, Samantha-
dc.contributor.authorKyaw, Htoo-
dc.contributor.authorYadav, Mayank-
dc.contributor.authorZhang, Zhongjie-
dc.contributor.authorHooda, Amit-
dc.contributor.authorFarooq, Ali-
dc.contributor.authorKrishnamoorthy, Parasuram-
dc.contributor.authorSweeny, Joseph M-
dc.contributor.authorKhera, Sahil-
dc.contributor.authorSerrao, Gregory W-
dc.contributor.authorSharma, Raman-
dc.contributor.authorSuleman, Javed-
dc.contributor.authorDangas, George-
dc.contributor.authorKini, Annapoorna S-
dc.contributor.authorMehran, Roxana-
dc.contributor.authorSharma, Samin K-
dc.date.accessioned2023-01-12T03:02:38Z-
dc.date.available2023-01-12T03:02:38Z-
dc.date.issued2022-11-28-
dc.identifier.citationJACC. Cardiovascular Interventions 2022; 15(22)en_US
dc.identifier.issn1876-7605-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/31787-
dc.description.abstractPotent P2Y12 agents such as ticagrelor and prasugrel are increasingly utilized across the clinical spectrum of patients undergoing percutaneous coronary intervention (PCI). There is a paucity of data supporting their use in a patient population inclusive of both acute coronary syndrome (ACS) and chronic coronary syndrome (CCS) patients.en_US
dc.language.isoeng-
dc.subjectacute coronary syndromeen_US
dc.subjectantiplatelet therapyen_US
dc.subjectchronic coronary syndromeen_US
dc.subjectmajor adverse cardiovascular event(s)en_US
dc.subjectpercutaneous coronary interventionen_US
dc.subjectstable ischemic heart diseaseen_US
dc.titleTicagrelor vs Prasugrel in a Contemporary Real-World Cohort Undergoing Percutaneous Coronary Intervention.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleJACC. Cardiovascular Interventionsen_US
dc.identifier.affiliationThe Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA; Department of Cardiology, Austin Health, University of Melbourne, Melbourne, Victoria, Australia.en_US
dc.identifier.affiliationCardiologyen_US
dc.identifier.affiliationthe Center for Interventional Cardiovascular Research and Clinical Trials, The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USAen_US
dc.identifier.affiliationThe Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.en_US
dc.identifier.doi10.1016/j.jcin.2022.09.021en_US
dc.type.contentTexten_US
dc.identifier.pubmedid36423970-
dc.description.volume15-
dc.description.issue22-
dc.description.startpage2270-
dc.description.endpage2280-
dc.subject.meshtermssecondaryPrasugrel Hydrochloride/adverse effects-
dc.subject.meshtermssecondaryTicagrelor/adverse effects-
dc.subject.meshtermssecondaryPercutaneous Coronary Intervention/adverse effects-
dc.subject.meshtermssecondaryAcute Coronary Syndrome/diagnostic imaging-
dc.subject.meshtermssecondaryAcute Coronary Syndrome/therapy-
dc.subject.meshtermssecondaryStroke/etiology-
local.name.researcherKoshy, Anoop N
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
item.cerifentitytypePublications-
crisitem.author.deptCardiology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

40
checked on Jan 22, 2025

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.